BOVNF (BioInvent International AB) Tariff Resilience Score: 0/10 (As of Jul. 01, 2026)


BOVNF BioInvent International AB BOVNF
53 GF Score
Price $3.29
GF Value $6.77
! 4 Warning Signs
View Full Analysis

What is BioInvent International AB Tariff Resilience Score?

BioInvent International AB has the Tariff Resilience Score of 0, which implies that the company might have .

BioInvent International AB has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes BioInvent International AB might have .

BioInvent International AB  (OTCPK:BOVNF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

BioInvent International AB Tariff Resilience Score Related Terms

BOVNF
53GF Score
BioInvent International AB BOVNF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioInvent International AB (BOVNF) Overvalued in 2026?

Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued. The current stock price of $3.29 is trading 51.4% below its estimated GF Value™ of $6.77.

Key valuation signals for BOVNF:

  • Tariff Resilience Score: 0
  • GF Value™: $6.77 vs. price of $3.29 (51.4% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the BOVNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioInvent International AB Business Description

Address Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
53GF Score

Get the complete analysis for BOVNF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.29
Price
$6.77
GF Value